Vaccine adjuvants stimulate the adaptive immune system to produce antibodies against the given antigen. Vaccine adjuvants using heterogeneous Monophosphoryl Lipid A (MPL) derived from Salmonella minnesota R595 have proven to be safe and effective at inducing Th-1 type immune responses to heterologous proteins in animal and human vaccines. Avanti has revolutionized immunotherapy and vaccine development with the introduction of Synthetic Monophosphoryl Lipid A (MPL) derivatives and adjuvant systems. We manufacture multiple synthetic analogs of MPL containing a single molecular species that are as effective and safe at inducing an immune response as their natural product predecessor. To discuss our adjuvants manufactured according to cGMP guidelines and available for clinical trials, please contact us at Licensing opportunities are available for your field of use.

Many vaccines use a combination of adjuvants to tailor specific immune responses. Avanti’s TDB and DDA products have been found to be useful adjuvants in combination with each other for a number of disease targets.

Avanti is ready to support your adjuvant formulation development activities and continue working toward more effective adjuvants and adjuvant combinations to support global health strategies and prevent future pandemics.